Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessGeron Corporation's Financial Performance in the Biopharmaceutical Sector

Geron Corporation’s Financial Performance in the Biopharmaceutical Sector

Add to Favorite
Added to Favorite


Geron Corporation (NASDAQ:GERN) has a ROIC of -34.35%, indicating it is not generating returns above its cost of capital.
Comparatively, Stem, Inc. (STEM) and Agenus Inc. (AGEN) also show negative ROIC, with Agenus displaying significant capital utilization inefficiencies.
Exelixis, Inc. (EXEL) demonstrates positive financial performance with a ROIC of 18.19%, suggesting efficient capital utilization and growth potential.

Geron Corporation (NASDAQ:GERN) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer treatment. The company invests heavily in research and development, which is typical for firms in this sector. This often results in a negative Return on Invested Capital (ROIC) of -34.35% as they work towards bringing their products to market.

Geron’s ROIC is significantly lower than its Weighted Average Cost of Capital (WACC) of 8.21%. This indicates that Geron is not currently generating returns that exceed its cost of capital. This is a common scenario for companies in the clinical-stage biopharmaceutical sector, where significant investments are made in research and development before achieving profitability.

In comparison, Stem, Inc. (STEM) has a ROIC of -0.09% and a WACC of 4.75%, resulting in a ROIC to WACC ratio of -0.02. While still negative, Stem’s ratio is closer to breakeven compared to Geron, suggesting slightly better capital efficiency. This indicates that Stem is managing its capital more effectively, despite not yet achieving positive returns.

Agenus Inc. (AGEN) presents a more challenging scenario with a ROIC of -813.12% and a WACC of 90.68%, leading to a ROIC to WACC ratio of -8.97. This highlights significant inefficiencies in capital utilization, which is a concern for investors. Agenus, like Geron, is in the early stages of drug development, which often involves high costs and uncertain returns.

Exelixis, Inc. (EXEL) stands out with a positive ROIC of 18.19% and a WACC of 6.72%, resulting in a ROIC to WACC ratio of 2.71. This indicates that Exelixis is generating returns well above its cost of capital, suggesting efficient capital utilization and potential for growth. Exelixis’s strong financial performance makes it a standout among its peers.

Subscribe to get Latest News Updates

Latest News

You may like more
more